Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Lexapro (escitalopram) is not known to cause permanent structural brain damage, though it does temporarily alter serotonin signaling, and most cognitive or emotional blunting effects resolve after the medication is stopped or adjusted. Sexual side effects such as low libido, delayed orgasm, or erectile difficulty are common during treatment and usually reverse after discontinuation, but a rare condition called post-SSRI sexual dysfunction (PSSD) has been reported to persist for months or longer in a small number of people. Several factors matter here, including dose, duration of use, age, and whether symptoms began during treatment or after stopping, so see below to understand more before drawing conclusions about your own situation.
Because lingering brain fog, mood flatness, and sexual changes can also stem from depression itself, thyroid problems, hormonal shifts, or other medications, guessing at the cause can delay the right care. A free, instant, online symptom check can help you sort out which explanation best fits your pattern and what to raise with your prescriber next.
Last reviewed for medical accuracy: 09/13/2026
Lexapro (escitalopram) is a commonly prescribed selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety. Like all medications, it carries potential side effects. Two questions often arise:
Below, we review what credible research tells us and offer practical guidance.
Lexapro increases levels of serotonin, a brain chemical that helps regulate mood and anxiety. It:
Most people experience relief from depressive or anxious symptoms without permanent alterations to brain structure or function.
SSRIs like Lexapro can trigger neuroplastic changes—adjustments in how neurons connect and communicate. These shifts:
Current studies find no clear evidence that Lexapro causes harmful, permanent brain changes. Key points:
It’s important to distinguish normal adjustments in brain chemistry from irreversible damage. SSRIs are among the most studied psychiatric medications, and long-term safety data do not support permanent harms when used as directed.
Sexual side effects are among the most reported concerns for people taking SSRIs. With Lexapro, these may include:
Most people notice improvement in mood but also experience one or more of these effects. Estimates vary, but up to 30–50% of SSRI users report some sexual side effect.
A small subset of individuals describe persistent sexual issues after stopping SSRIs, sometimes termed Post-SSRI Sexual Dysfunction (PSSD). While research is ongoing, current understanding is:
If you suspect PSSD, speak with a healthcare professional. Early recognition may improve the chance of recovery.
If you’re on Lexapro and experiencing sexual side effects, consider these strategies:
Always discuss any change with your prescribing doctor to avoid withdrawal or mood relapse.
While taking Lexapro, you can support your brain and overall well-being by:
These lifestyle measures enhance treatment outcomes and promote long-term mental health.
Regular check-ins with your doctor or mental health provider help ensure:
If you notice concerning changes—especially suicidal thoughts, severe mood swings, or troubling sexual symptoms—seek medical advice immediately.
You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to track side effects and discuss them in your next appointment.
Some reactions may signal serious or life-threatening issues. Contact a doctor or emergency services if you experience:
Prompt attention can be life-saving.
Permanent brain damage?
No strong evidence supports lasting harm from Lexapro when used as prescribed. Neuroplastic changes tend to reverse after stopping.
Sexual side effects?
Common while on SSRIs and usually improve after discontinuation. Rare cases of persistent issues (PSSD) exist but remain under study.
Managing side effects
Dose adjustments, medication switches, add-on therapies, and lifestyle changes can help.
Stay informed and proactive
Regular medical follow-up, healthy habits, and open communication with your doctor are crucial.
Always speak to a doctor about any serious or life-threatening symptoms. Your healthcare provider can tailor treatment to your needs, balancing benefits and side effects for your best outcome.
(References)
* Drugs for Depression. Med Lett Drugs Ther. 2020 Feb 24;62(1592):25-32. PMID: 32320387.
* Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. 2022 Apr;111(4):886-895. doi: 10.1002/cpt.2487. Epub 2021 Nov 22. PMID: 34743319; PMCID: PMC9299061.
* Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. PMID: 35411074.
* Wang Y, Zhou J, Ye J, Sun Z, He Y, Zhao Y, Ren S, Zhang G, Liu M, Zheng P, Wang G, Yang J. Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder. Microbiome. 2023 Aug 28;11(1):195. doi: 10.1186/s40168-023-01635-6. Epub 2023 Aug 28. PMID: 37641148; PMCID: PMC10464022.
* Drugs for depression. Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200. doi: 10.58347/tml.2023.1691a. PMID: 38133585.
* Yan N, Hu S. The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial. BMC Psychiatry. 2024 May 15;24(1):365. doi: 10.1186/s12888-024-05833-w. Epub 2024 May 15. PMID: 38750479; PMCID: PMC11094958.
* Zivko C, Sagar R, Xydia A, Lopez-Montes A, Mintzer J, Rosenberg PB, Shade DM, Porsteinsson AP, Lyketsos CG, Mahairaki V. iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease. Mol Psychiatry. 2024 Nov;29(11):3644-3652. doi: 10.1038/s41380-024-02629-y. Epub 2024 Jun 5. PMID: 38840027; PMCID: PMC11541203.
* Tan J, Xiao Y, Kong F, Zhang X, Xu H, Zhu A, Liu Y, Lei J, Tian B, Yuan Y, Yan C. Molecular basis of human noradrenaline transporter reuptake and inhibition. Nature. 2024 Aug;632(8026):921-929. doi: 10.1038/s41586-024-07719-z. Epub 2024 Jul 24. PMID: 39048818.
* Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, Nutt DJ, Carhart-Harris RL. Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression. Am J Psychiatry. 2025 Jun 1;182(6):569-582. doi: 10.1176/appi.ajp.20230751. Epub 2025 May 7. PMID: 40329640.
* Shin J, Lee KH, Kim JW. Effects of escitalopram on resting-state functional connectivity in comorbid depressive and anxious adolescents. J Affect Disord. 2026 Jul 15;405:121567. doi: 10.1016/j.jad.2026.121567. Epub 2026 Mar 9. PMID: 41812896.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.